250 related articles for article (PubMed ID: 25712455)
1. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
3. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
4. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
5. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
6. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Deininger MW; Hodgson JG; Shah NP; Cortes JE; Kim DW; Nicolini FE; Talpaz M; Baccarani M; Müller MC; Li J; Parker WT; Lustgarten S; Clackson T; Haluska FG; Guilhot F; Kantarjian HM; Soverini S; Hochhaus A; Hughes TP; Rivera VM; Branford S
Blood; 2016 Feb; 127(6):703-12. PubMed ID: 26603839
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
12. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
14. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells.
Tezcanli Kaymaz B; Gumus N; Celik B; Alcitepe İ; Biray Avci C; Aktan C
J Interferon Cytokine Res; 2024 Apr; 44(4):178-189. PubMed ID: 38579140
[TBL] [Abstract][Full Text] [Related]
16. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
18. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]